| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2802215401010 | 221540101 | FLUDARA PD.I.S.INF 50MG/VIAL BTx5 VIALS | 104.51 | 109.63 | 134.80 |
| 05/2018 | 2802215402024 | 221540202 | FLUDARA F.C.TAB 10MG/TAB BTx20 (BLIST 4x5) | 234.33 | 237.85 | 282.38 |
For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen
Fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. This metabolite appears to act by inhibiting DNA polymerase alpha, ribonucleotide reductase and DNA primase, thus inhibiting DNA synthesis. The mechanism of action of this antimetabolite is not completely characterized and may be multi-faceted.
Bioavailability is 55% following oral administration.
20 hours
* 117-145 mL/min [patients with B-cell CLL receiving IV administration of a single dose of 40 mg/m2]